Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

Michael Trauner, Frederik Nevens, Mitchell L. Shiffman, Joost P.H. Drenth, Christopher Bowlus, Victor Vargas, Pietro Andreone, Gideon M. Hirschfield, Richard Pencek, Elizabeth Smoot Malecha, Leigh MacConell, David Shapiro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. Methods: In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). Findings: 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change −105·2 U/L [SD 87·6]), 24 months (−101·0 U/L [98·5]), 36 months (−108·6 U/L [95·7]), and 48 months (−95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change −0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (−0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change −0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. Interpretation: Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. Funding: Intercept Pharmaceuticals.

Original languageEnglish (US)
Pages (from-to)445-453
Number of pages9
JournalThe Lancet Gastroenterology and Hepatology
Volume4
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Cholangitis
Safety
Bilirubin
Ursodeoxycholic Acid
Alkaline Phosphatase
6-ethylchenodeoxycholic acid
Cholestasis
Pruritus
Double-Blind Method
Fatigue
Placebos
Liver
Wounds and Injuries

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis : 3-year results of an international open-label extension study. / Trauner, Michael; Nevens, Frederik; Shiffman, Mitchell L.; Drenth, Joost P.H.; Bowlus, Christopher; Vargas, Victor; Andreone, Pietro; Hirschfield, Gideon M.; Pencek, Richard; Malecha, Elizabeth Smoot; MacConell, Leigh; Shapiro, David.

In: The Lancet Gastroenterology and Hepatology, Vol. 4, No. 6, 01.06.2019, p. 445-453.

Research output: Contribution to journalArticle

Trauner, M, Nevens, F, Shiffman, ML, Drenth, JPH, Bowlus, C, Vargas, V, Andreone, P, Hirschfield, GM, Pencek, R, Malecha, ES, MacConell, L & Shapiro, D 2019, 'Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study', The Lancet Gastroenterology and Hepatology, vol. 4, no. 6, pp. 445-453. https://doi.org/10.1016/S2468-1253(19)30094-9
Trauner, Michael ; Nevens, Frederik ; Shiffman, Mitchell L. ; Drenth, Joost P.H. ; Bowlus, Christopher ; Vargas, Victor ; Andreone, Pietro ; Hirschfield, Gideon M. ; Pencek, Richard ; Malecha, Elizabeth Smoot ; MacConell, Leigh ; Shapiro, David. / Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis : 3-year results of an international open-label extension study. In: The Lancet Gastroenterology and Hepatology. 2019 ; Vol. 4, No. 6. pp. 445-453.
@article{dd9850034b534127aa0a6374758a9369,
title = "Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study",
abstract = "Background: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. Methods: In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). Findings: 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change −105·2 U/L [SD 87·6]), 24 months (−101·0 U/L [98·5]), 36 months (−108·6 U/L [95·7]), and 48 months (−95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change −0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (−0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change −0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77{\%}] patients) and fatigue (63 [33{\%}]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. Interpretation: Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. Funding: Intercept Pharmaceuticals.",
author = "Michael Trauner and Frederik Nevens and Shiffman, {Mitchell L.} and Drenth, {Joost P.H.} and Christopher Bowlus and Victor Vargas and Pietro Andreone and Hirschfield, {Gideon M.} and Richard Pencek and Malecha, {Elizabeth Smoot} and Leigh MacConell and David Shapiro",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/S2468-1253(19)30094-9",
language = "English (US)",
volume = "4",
pages = "445--453",
journal = "The Lancet Gastroenterology and Hepatology",
issn = "2468-1253",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis

T2 - 3-year results of an international open-label extension study

AU - Trauner, Michael

AU - Nevens, Frederik

AU - Shiffman, Mitchell L.

AU - Drenth, Joost P.H.

AU - Bowlus, Christopher

AU - Vargas, Victor

AU - Andreone, Pietro

AU - Hirschfield, Gideon M.

AU - Pencek, Richard

AU - Malecha, Elizabeth Smoot

AU - MacConell, Leigh

AU - Shapiro, David

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. Methods: In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). Findings: 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change −105·2 U/L [SD 87·6]), 24 months (−101·0 U/L [98·5]), 36 months (−108·6 U/L [95·7]), and 48 months (−95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change −0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (−0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change −0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. Interpretation: Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. Funding: Intercept Pharmaceuticals.

AB - Background: The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. Methods: In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). Findings: 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change −105·2 U/L [SD 87·6]), 24 months (−101·0 U/L [98·5]), 36 months (−108·6 U/L [95·7]), and 48 months (−95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change −0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (−0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change −0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. Interpretation: Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. Funding: Intercept Pharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=85065082102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065082102&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(19)30094-9

DO - 10.1016/S2468-1253(19)30094-9

M3 - Article

C2 - 30922873

AN - SCOPUS:85065082102

VL - 4

SP - 445

EP - 453

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

SN - 2468-1253

IS - 6

ER -